diff --git "a/6585c72e-9956-46d2-9cdc-dc11218b73cf.json" "b/6585c72e-9956-46d2-9cdc-dc11218b73cf.json" new file mode 100644--- /dev/null +++ "b/6585c72e-9956-46d2-9cdc-dc11218b73cf.json" @@ -0,0 +1,40 @@ +{ + "interaction_id": "6585c72e-9956-46d2-9cdc-dc11218b73cf", + "search_results": [ + { + "page_name": "Should You Buy Gritstone Oncology Inc (GRTS) Stock Friday?", + "page_url": "https://www.investorsobserver.com/news/stock-update/should-you-buy-gritstone-oncology-inc-grts-stock-friday", + "page_snippet": "GRTS's short-term technical score ... over the last month than 100% of stocks on the market. In the Biotechnology industry, which ranks 94 out of 146 industries, GRTS ranks higher than 100% of stocks. Gritstone Oncology Inc has risen 664.97% over the past month, closing at $3.70 on December 25. During this period of time, the stock fell as low as $3.70 and as high as $35.20. GRTS has an average analyst recommendation of Buy. The company has an average price target of ...GRTS's short-term technical score of 100 indicates that the stock has traded more bullishly over the last month than 100% of stocks on the market. In the Biotechnology industry, which ranks 94 out of 146 industries, GRTS ranks higher than 100% of stocks. Gritstone Oncology Inc has risen 664.97% over the past month, closing at $3.70 on December 25. During this period of time, the stock fell as low as $3.70 and as high as $35.20. GRTS has an average analyst recommendation of Buy. The company has an average price target of $16.33. The company has an average price target of $16.33. GRTS has an Overall Score of 67. Find out what this means to you and get the rest of the rankings on GRTS! ... Gritstone Oncology Inc has a Long-Term Technical rank of 100. This means that trading over the last 200 trading days has placed the company in the upper half of stocks with 0% of the market scoring higher. Gritstone Oncology Inc (Gritstone Oncology Inc (GRTS)) has fallen Friday morning, with the stock decreasing -5.64% in pre-market trading to 24.11. GRTS's short-term technical score of 100 indicates that the stock has traded more bullishly over the last month than 100% of stocks on the market. This means that trading over the last 200 trading days has placed the company in the upper half of stocks with 0% of the market scoring higher. In the Biotechnology industry which is number 91 by this metric, GRTS ranks better than 100% of stocks. ... -Gritstone Oncology Inc is set to release earnings on 3/10/2021.", + "page_result": "\n\n\n \n \n\n \n \n \n Should You Buy Gritstone Oncology Inc (GRTS) Stock Friday?\n \n \n\n \n \n \n \n \n \n \n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n \n \n \n \n \n \n\n\n\n\n
\n
\n
\n \n \n \"InvestorsObserver\"\n \n
\n \n
\n \n \n
\n
\n
\n
\n
\n
\n
\n \n
\n
\n
\n
\n
\n
\n
    \n
\n
\n
\n
\n
\n
\n\n\n
\n\n
\n\n \n
\n
\n \n
\n
\n \n
\n Sign Up\n Login\n
\n
\n
\n
\n
\n
\n
\n \n \n \n
\n\n
\n \n
\n
\n\n
\n
\n \n
\n ×\n \n
\n
\n\n
\n
\n \n\n
\n
\n
\n
\n \n \n \n
\n
\n
\n News Home\n \n

Should You Buy Gritstone Oncology Inc (GRTS) Stock Friday?

\n
\n Friday, January 22, 2021 08:06 AM | InvestorsObserver Analysts\n
\n \n
\n

Mentioned in this article

\n \n
\n \n
\n \"Should\n
\n
\n \n

Gritstone Oncology Inc (Gritstone Oncology Inc (GRTS)) has fallen Friday morning, with the stock decreasing -5.64% in pre-market trading to 24.11.

\n

GRTS's short-term technical score of 100 indicates that the stock has traded more bullishly over the last month than 100% of stocks on the market. In the Biotechnology industry, which ranks 94 out of 146 industries, GRTS ranks higher than 100% of stocks.

\n

Gritstone Oncology Inc has risen 664.97% over the past month, closing at $3.70 on December 25. During this period of time, the stock fell as low as $3.70 and as high as $35.20. GRTS has an average analyst recommendation of Buy. The company has an average price target of $16.33.

\n
\n
Overall Score - 67
\n
GRTS has an Overall Score of 67. Find out what this means to you and get the rest of the rankings on GRTS!\n
See Full GRTS Report
\n
\n
\n\n

Gritstone Oncology Inc has a Long-Term Technical rank of 100. This means that trading over the last 200 trading days has placed the company in the upper half of stocks with 0% of the market scoring higher. In the Biotechnology industry which is number 91 by this metric, GRTS ranks better than 100% of stocks.

\n

Important Dates for Investors in GRTS:

\n

-Gritstone Oncology Inc is set to release earnings on 3/10/2021. During their last earnings release the company posted EPS of $-2.86.\n-We do not have a set dividend date for Gritstone Oncology Inc at this time.\nClick Here to get the full Stock Score Report on Gritstone Oncology Inc (GRTS) Stock.

\n\n
\n\n
\n

Share this article:

\n \n
\n \n
\n

Stay In The Know

\n

Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.

\n\n
\n\n \n\n
\n
\n
\n\n
\n
\n

Thank you for signing up! You're all set to receive the Morning Update newsletter

\n
\n
\n
\n\n\n \n
\n\n
\n
\n

Related Articles

\n \n
\n
\n
\n
\n

Related Companies

\n \n
\n
\n\n

You May Also Like

\n\n\n\n
\n
\n\n \n \n
\n
\n
\n
\n
\n\n\n
\n\n\n
\n
\n \n

Get the InvestorsObserver App

\n
\n \"InvestorsObserver\n\n
\n
\n \"iOS\n \"Android\n
\n
\n
\n\n\n\n", + "page_last_modified": "" + }, + { + "page_name": "GRTS | Gritstone bio Inc. Stock Overview (U.S.: Nasdaq) | Barron's", + "page_url": "https://www.barrons.com/market-data/stocks/grts", + "page_snippet": "Complete Gritstone bio Inc. stock information by Barron's. View real-time GRTS stock price and news, along with industry-best analysis.Commodities & Futures: Futures prices are delayed at least 10 minutes as per exchange requirements. Change value during the period between open outcry settle and the commencement of the next day's trading is calculated as the difference between the last trade and the prior day's settle. Mutual Funds & ETFs: All of the mutual fund and ETF information contained in this display, with the exception of the current price and price history, was supplied by Lipper, A Refinitiv Company, subject to the following: Copyright 2019\u00a9 Refinitiv. All rights reserved.", + "page_result": "GRTS | Gritstone bio Inc. Stock Overview (U.S.: Nasdaq) | Barron's
\n \n \n \n \n
\n
\"Barron's
Stock PicksLists & RankingsMagazineDataAdvisorPenta
Summary
Summary
U.S
Europe
Asia
FX
Rates
Futures
ETFs
Crypto
DJIA
S&P 500
NASDAQ
Russell 2000
U.S. 10 Yr
VIX
Bitcoin
Crude Oil
Dollar Index
Future Index
Barron's 400
  1. Market Data
    2. /
  2. Stocks
    3. /
  3. GRTS
    4. /
  4. Overview

Gritstone bio Inc.

U.S.: Nasdaq
Add to Watchlist
0.00
GRTS
Real Time Quote
About Gritstone bio Inc.
Gritstone bio, Inc. clinical-stage biotechnology company, which engages in developing the next generation of cancer immunotherapies to fight multiple cancer types. The company was founded by Andrew Allen, Timothy Chan, Mark Cobbold, Graham Lord, Naiyer Rizvi and Jean-Charles Soria in August 2015 and is headquartered in Emeryville, CA.
See Full Profile

Analyst Ratings

Average price target from 8 ratings: $9.00

Average score:

Sell
Under
Hold
Over
Buy
Full Ratings

StockGrader

Rating:
Sentiment:
\"PoweredFull Analysis
Open
$2.7600
Previous Close-
YTD Change
31.86%
12 Month Change
12.55%
Day Range2.6000 - 2.8000
52 Wk Range1.1393 - 3.3300
Volume
636.09K (34.14% of Avg)
65 Day Avg: 1.86M
Volume1.86M
Market Value$260.28M
Shares Outstanding95.34M
EPS (TTM)-$1.2971
P/E Ratio (TTM)N/A
Dividend YieldN/A
Latest DividendN/A
Ex-Dividend DateN/A
Beta1.36
Short Interest9.14M (02/15/24)
Short Interest Change1.64%
Percent of Float10.52%
Advanced
$
1D
Compare

Peers

Name
Chg %
Market Cap
Eli Lilly & Co.
-0.90%
$733.45B
Merck & Co. Inc.
0.15%
$326.48B
Moderna Inc.
2.32%
$35.92B
BioNTech SE ADR
-0.78%
$22.23B
CureVac N.V.
4.68%
$765.68M
Nykode Therapeutics A/S
-5.67%
kr5.79B
Achilles Therapeutics PLC ADR
9.56%
$55.46M

Recently Viewed

Symbol
% Chg
Price
OverviewCompany & PeopleFinancialsResearch & RatingsStockGraderAdvanced Chart

news

Loading data

People

Key Executives
Board Members
Andrew R Allen MD, PhD
President, Chief Executive Officer & Director
Elaine V Jones PhD
Chairman
Erin E Jones
Chief Operating Officer & Executive Vice President
Steve E Krognes MBA
Independent Director
Vassiliki Celia Economides
Chief Financial Officer & Executive Vice President
Clare Fisher MBA
Independent Director
See All on Company & People

Major Holders

No data provided

Financials

2022
Revenue
9.27M
Net Income
-119.69M
Net Profit Margin
-1,291.26%
2022
Total Assets
240.75M
Total Liabilities
69.97M
Debt to Assets
29.06%
2022
Operating
-115.95M
Investing
-12.96M
Financing
83.1M
See All Financials
\n

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock quotes are delayed as per exchange requirements. Fundamental company data and analyst estimates provided by FactSet. Copyright 2019\u00a9 FactSet Research Systems Inc. All rights reserved. Source: FactSet

\n

Indexes: Index quotes may be real-time or delayed as per exchange requirements; refer to time stamps for information on any delays. Source: FactSet

\n

Markets Diary: Data on U.S. Overview page represent trading in all U.S. markets and updates until 8 p.m. See Closing Diaries table for 4 p.m. closing data. Sources: FactSet, Dow Jones

\n

Stock Movers: Gainers, decliners and most actives market activity tables are a combination of NYSE, Nasdaq, NYSE American and NYSE Arca listings. Sources: FactSet, Dow Jones

\n

ETF Movers: Includes ETFs & ETNs with volume of at least 50,000. Sources: FactSet, Dow Jones

\n

Bonds: Bond quotes are updated in real-time. Sources: FactSet, Tullett Prebon

\n

Currencies: Currency quotes are updated in real-time. Sources: FactSet, Tullett Prebon

\n

Commodities & Futures: Futures prices are delayed at least 10 minutes as per exchange requirements. Change value during the period between open outcry settle and the commencement of the next day's trading is calculated as the difference between the last trade and the prior day's settle. Change value during other periods is calculated as the difference between the last trade and the most recent settle. Source: FactSet

\n \n

Data are provided 'as is' for informational purposes only and are not intended for trading purposes. FactSet (a) does not make any express or implied warranties of any kind regarding the data, including, without limitation, any warranty of merchantability or fitness for a particular purpose or use; and (b) shall not be liable for any errors, incompleteness, interruption or delay, action taken in reliance on any data, or for any damages resulting therefrom. Data may be intentionally delayed pursuant to supplier requirements.

\n

Mutual Funds & ETFs: All of the mutual fund and ETF information contained in this display, with the exception of the current price and price history, was supplied by Lipper, A Refinitiv Company, subject to the following: Copyright 2019\u00a9 Refinitiv. All rights reserved. Any copying, republication or redistribution of Lipper content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Lipper. Lipper shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

\n

Cryptocurrencies: Cryptocurrency quotes are updated in real-time. Sources: CoinDesk (Bitcoin), Kraken (all other cryptocurrencies)

\n

Calendars and Economy: 'Actual' numbers are added to the table after economic reports are released. Source: Kantar Media

\n
Barron's

Topics

Memberships

Tools

Customer Service

Network

Newsstand

For Business

For Education

For Advertisers

Account

About Barron's

Privacy Notice
Cookie Notice
Copyright Policy
Accessibility
Data Policy
Your Ad Choices
Subscriber Agreement & Terms of Use
Community Rules
Barron's Archive
Copyright \u00a9 2024 Dow Jones & Company, Inc. All Rights Reserved.\n
\n \n \n \n \n \n \n \n \n \n \n \n \n
", + "page_last_modified": "" + }, + { + "page_name": "GRTS | Gritstone bio Inc. Stock Price & News - WSJ", + "page_url": "https://www.wsj.com/market-data/quotes/us/GRTS", + "page_snippet": "View the latest Gritstone bio Inc. (GRTS) stock price, news, historical charts, analyst ratings and financial information from WSJ.A company's dividend expressed as a percentage of its current stock price. ... GRTS is not currently paying a regular dividend. ... The total number of shares of a security that have been sold short and not yet repurchased. Commodities & Futures: Futures prices are delayed at least 10 minutes as per exchange requirements. Change value during the period between open outcry settle and the commencement of the next day's trading is calculated as the difference between the last trade and the prior day's settle. Change value during other periods is calculated as the difference between the last trade and the most recent settle. Source: FactSet \u00b7 Data are provided 'as is' for informational purposes only and are not intended for trading purposes. FactSet (a) does not make any express or implied warranties of any kind regarding the data, including, without limitation, any warranty of merchantability or fitness for a particular purpose or use; and (b) shall not be liable for any errors, incompleteness, interruption or delay, action taken in reliance on any data, or for any damages resulting therefrom. The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for the trailing 12 month period.", + "page_result": "\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\n\n\n\n\n\n\n\n\n\n\n \n \n \n \n \n \n GRTS | Gritstone bio Inc. Stock Price & News - WSJ\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n if (window.__ace && typeof window.__ace === 'function') {\n const id = '61f2bdf7b00575078c959fee';\n const cb = () => {\n const vendorScript = document.createElement('script');\n vendorScript.src = 'https://d3icekm41k795y.cloudfront.net/rsxvmxxqlm.js';\n vendorScript.setAttribute('id', 'adtoniq');\n vendorScript.async = true;\n vendorScript.addEventListener('load', function () { window.__ace('page', 'setPerfMark', ['adtoniq-loaded']);window.__ace('adtoniq', 'initListener', ['154a3e38-2228-44d6-9db6-c9707f3647ea']); });\n document.body.appendChild(vendorScript);\n }\n __ace('djcmp', 'executeOnCmpReady', [{cb, id }]);\n };\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n
\n \n
\n

The Wall Street Journal

English Edition
More

\n
\n \n \n \n
View All Companies

Gritstone bio Inc.

GRTS (U.S.: Nasdaq)
Overview
Profile
Financials
Income Statement
Balance Sheet
Cash Flow
Research & Ratings
Historical Prices
Options
Advanced Charting

NewsGritstone bio Inc.GRTS

No significant news for in the past two years.
Key Stock Data
P/E Ratio (TTM)
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for the trailing 12 month period.
Earnings Per Share (TTM)
A company's net income for the trailing twelve month period expressed as a dollar amount per fully diluted shares outstanding.
Market Capitalization
Reflects the total market value of a company. Market Cap is calculated by multiplying the number of shares outstanding by the stock's price. For companies with multiple common share classes, market capitalization includes both classes.
Shares Outstanding
Number of shares that are currently held by investors, including restricted shares owned by the company's officers and insiders as well as those held by the public.
Public Float
The number of shares in the hands of public investors and available to trade. To calculate, start with total shares outstanding and subtract the number of restricted shares. Restricted stock typically is that issued to company insiders with limits on when it may be traded.
Dividend Yield
A company's dividend expressed as a percentage of its current stock price.

Key Stock Data

  • P/E Ratio (TTM)
    N/A
  • EPS (TTM)
    $-1.30
  • Market Cap
    $260.28 M
  • Shares Outstanding
    95.34 M
  • Public Float
    86.93 M
  • Yield
    GRTS is not currently paying a regular dividend.
  • Latest Dividend
    N/A
  • Ex-Dividend Date
    N/A
Shares Sold Short
The total number of shares of a security that have been sold short and not yet repurchased.
Change from Last
Percentage change in short interest from the previous report to the most recent report. Exchanges report short interest twice a month.
Percent of Float
Total short positions relative to the number of shares available to trade.

Short Interest (02/15/24)

  • Shares Sold Short
    9.14 M
  • Change from Last
    1.64%
  • Percent of Float
    10.52%
Money Flow Uptick/Downtick Ratio
Money flow measures the relative buying and selling pressure on a stock, based on the value of trades made on an "uptick" in price and the value of trades made on a "downtick" in price. The up/down ratio is calculated by dividing the value of uptick trades by the value of downtick trades. Net money flow is the value of uptick trades minus the value of downtick trades. Our calculations are based on comprehensive, delayed quotes.

Stock Money Flow

  • N/A

Research & Ratings Gritstone bio Inc.(GRTS)

Per-Share Earnings, Actuals and Estimates

Actual Analyst Range Consensus
\n
\n \n \n \n
Overview
\n

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock quotes are delayed as per exchange requirements. Fundamental company data and analyst estimates provided by FactSet. Copyright 2019\u00a9 FactSet Research Systems Inc. All rights reserved. Source: FactSet

\n

Indexes: Index quotes may be real-time or delayed as per exchange requirements; refer to time stamps for information on any delays. Source: FactSet

\n

Markets Diary: Data on U.S. Overview page represent trading in all U.S. markets and updates until 8 p.m. See Closing Diaries table for 4 p.m. closing data. Sources: FactSet, Dow Jones

\n

Stock Movers: Gainers, decliners and most actives market activity tables are a combination of NYSE, Nasdaq, NYSE American and NYSE Arca listings. Sources: FactSet, Dow Jones

\n

ETF Movers: Includes ETFs & ETNs with volume of at least 50,000. Sources: FactSet, Dow Jones

\n

Bonds: Bond quotes are updated in real-time. Sources: FactSet, Tullett Prebon

\n

Currencies: Currency quotes are updated in real-time. Sources: FactSet, Tullett Prebon

\n

Commodities & Futures: Futures prices are delayed at least 10 minutes as per exchange requirements. Change value during the period between open outcry settle and the commencement of the next day's trading is calculated as the difference between the last trade and the prior day's settle. Change value during other periods is calculated as the difference between the last trade and the most recent settle. Source: FactSet

\n \n

Data are provided 'as is' for informational purposes only and are not intended for trading purposes. FactSet (a) does not make any express or implied warranties of any kind regarding the data, including, without limitation, any warranty of merchantability or fitness for a particular purpose or use; and (b) shall not be liable for any errors, incompleteness, interruption or delay, action taken in reliance on any data, or for any damages resulting therefrom. Data may be intentionally delayed pursuant to supplier requirements.

\n

Mutual Funds & ETFs: All of the mutual fund and ETF information contained in this display, with the exception of the current price and price history, was supplied by Lipper, A Refinitiv Company, subject to the following: Copyright 2019\u00a9 Refinitiv. All rights reserved. Any copying, republication or redistribution of Lipper content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Lipper. Lipper shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

\n

Cryptocurrencies: Cryptocurrency quotes are updated in real-time. Sources: CoinDesk (Bitcoin), Kraken (all other cryptocurrencies)

\n

Calendars and Economy: 'Actual' numbers are added to the table after economic reports are released. Source: Kantar Media

\n
\n \n \n \n \n\n \n \n \n \n \n \n \n \n \n\n\n \n \n ", + "page_last_modified": "" + }, + { + "page_name": "GRTS | Gritstone bio Inc. Stock Price & News - WSJ", + "page_url": "https://www.wsj.com/market-data/quotes/us/GRTS", + "page_snippet": "View the latest Gritstone bio Inc. (GRTS) stock price, news, historical charts, analyst ratings and financial information from WSJ.A company's dividend expressed as a percentage of its current stock price. ... GRTS is not currently paying a regular dividend. ... The total number of shares of a security that have been sold short and not yet repurchased. Commodities & Futures: Futures prices are delayed at least 10 minutes as per exchange requirements. Change value during the period between open outcry settle and the commencement of the next day's trading is calculated as the difference between the last trade and the prior day's settle. Change value during other periods is calculated as the difference between the last trade and the most recent settle. Source: FactSet \u00b7 Data are provided 'as is' for informational purposes only and are not intended for trading purposes. FactSet (a) does not make any express or implied warranties of any kind regarding the data, including, without limitation, any warranty of merchantability or fitness for a particular purpose or use; and (b) shall not be liable for any errors, incompleteness, interruption or delay, action taken in reliance on any data, or for any damages resulting therefrom. The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for the trailing 12 month period.", + "page_result": "\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\n\n\n\n\n\n\n\n\n\n\n \n \n \n \n \n \n GRTS | Gritstone bio Inc. Stock Price & News - WSJ\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n if (window.__ace && typeof window.__ace === 'function') {\n const id = '61f2bdf7b00575078c959fee';\n const cb = () => {\n const vendorScript = document.createElement('script');\n vendorScript.src = 'https://d3icekm41k795y.cloudfront.net/rsxvmxxqlm.js';\n vendorScript.setAttribute('id', 'adtoniq');\n vendorScript.async = true;\n vendorScript.addEventListener('load', function () { window.__ace('page', 'setPerfMark', ['adtoniq-loaded']);window.__ace('adtoniq', 'initListener', ['154a3e38-2228-44d6-9db6-c9707f3647ea']); });\n document.body.appendChild(vendorScript);\n }\n __ace('djcmp', 'executeOnCmpReady', [{cb, id }]);\n };\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n
\n \n
\n

The Wall Street Journal

English Edition
More

\n
\n \n \n \n
View All Companies

Gritstone bio Inc.

GRTS (U.S.: Nasdaq)
Overview
Profile
Financials
Income Statement
Balance Sheet
Cash Flow
Research & Ratings
Historical Prices
Options
Advanced Charting

NewsGritstone bio Inc.GRTS

No significant news for in the past two years.
Key Stock Data
P/E Ratio (TTM)
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for the trailing 12 month period.
Earnings Per Share (TTM)
A company's net income for the trailing twelve month period expressed as a dollar amount per fully diluted shares outstanding.
Market Capitalization
Reflects the total market value of a company. Market Cap is calculated by multiplying the number of shares outstanding by the stock's price. For companies with multiple common share classes, market capitalization includes both classes.
Shares Outstanding
Number of shares that are currently held by investors, including restricted shares owned by the company's officers and insiders as well as those held by the public.
Public Float
The number of shares in the hands of public investors and available to trade. To calculate, start with total shares outstanding and subtract the number of restricted shares. Restricted stock typically is that issued to company insiders with limits on when it may be traded.
Dividend Yield
A company's dividend expressed as a percentage of its current stock price.

Key Stock Data

  • P/E Ratio (TTM)
    N/A
  • EPS (TTM)
    $-1.30
  • Market Cap
    $260.28 M
  • Shares Outstanding
    95.34 M
  • Public Float
    86.93 M
  • Yield
    GRTS is not currently paying a regular dividend.
  • Latest Dividend
    N/A
  • Ex-Dividend Date
    N/A
Shares Sold Short
The total number of shares of a security that have been sold short and not yet repurchased.
Change from Last
Percentage change in short interest from the previous report to the most recent report. Exchanges report short interest twice a month.
Percent of Float
Total short positions relative to the number of shares available to trade.

Short Interest (02/15/24)

  • Shares Sold Short
    9.14 M
  • Change from Last
    1.64%
  • Percent of Float
    10.52%
Money Flow Uptick/Downtick Ratio
Money flow measures the relative buying and selling pressure on a stock, based on the value of trades made on an "uptick" in price and the value of trades made on a "downtick" in price. The up/down ratio is calculated by dividing the value of uptick trades by the value of downtick trades. Net money flow is the value of uptick trades minus the value of downtick trades. Our calculations are based on comprehensive, delayed quotes.

Stock Money Flow

  • N/A

Research & Ratings Gritstone bio Inc.(GRTS)

Per-Share Earnings, Actuals and Estimates

Actual Analyst Range Consensus
\n
\n \n \n \n
Overview
\n

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock quotes are delayed as per exchange requirements. Fundamental company data and analyst estimates provided by FactSet. Copyright 2019\u00a9 FactSet Research Systems Inc. All rights reserved. Source: FactSet

\n

Indexes: Index quotes may be real-time or delayed as per exchange requirements; refer to time stamps for information on any delays. Source: FactSet

\n

Markets Diary: Data on U.S. Overview page represent trading in all U.S. markets and updates until 8 p.m. See Closing Diaries table for 4 p.m. closing data. Sources: FactSet, Dow Jones

\n

Stock Movers: Gainers, decliners and most actives market activity tables are a combination of NYSE, Nasdaq, NYSE American and NYSE Arca listings. Sources: FactSet, Dow Jones

\n

ETF Movers: Includes ETFs & ETNs with volume of at least 50,000. Sources: FactSet, Dow Jones

\n

Bonds: Bond quotes are updated in real-time. Sources: FactSet, Tullett Prebon

\n

Currencies: Currency quotes are updated in real-time. Sources: FactSet, Tullett Prebon

\n

Commodities & Futures: Futures prices are delayed at least 10 minutes as per exchange requirements. Change value during the period between open outcry settle and the commencement of the next day's trading is calculated as the difference between the last trade and the prior day's settle. Change value during other periods is calculated as the difference between the last trade and the most recent settle. Source: FactSet

\n \n

Data are provided 'as is' for informational purposes only and are not intended for trading purposes. FactSet (a) does not make any express or implied warranties of any kind regarding the data, including, without limitation, any warranty of merchantability or fitness for a particular purpose or use; and (b) shall not be liable for any errors, incompleteness, interruption or delay, action taken in reliance on any data, or for any damages resulting therefrom. Data may be intentionally delayed pursuant to supplier requirements.

\n

Mutual Funds & ETFs: All of the mutual fund and ETF information contained in this display, with the exception of the current price and price history, was supplied by Lipper, A Refinitiv Company, subject to the following: Copyright 2019\u00a9 Refinitiv. All rights reserved. Any copying, republication or redistribution of Lipper content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Lipper. Lipper shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

\n

Cryptocurrencies: Cryptocurrency quotes are updated in real-time. Sources: CoinDesk (Bitcoin), Kraken (all other cryptocurrencies)

\n

Calendars and Economy: 'Actual' numbers are added to the table after economic reports are released. Source: Kantar Media

\n
\n \n \n \n \n\n \n \n \n \n \n \n \n \n \n\n\n \n \n ", + "page_last_modified": "" + }, + { + "page_name": "Gritstone Oncology Inc (GRTS) Stock Price, Quote, News & Analysis ...", + "page_url": "https://www.tipranks.com/stocks/grts", + "page_snippet": "Gritstone Oncology Inc (GRTS) has a Smart Score of 6 based on an analysis of 8 unique data sets, including Analyst Recommendations, Crowd Wisdom, and Hedge Fund Activity.\u200b\u200bGritstone Oncology Inc lowest stock price was $1.14 and its highest was $3.33 in the past 12 months. ... Gritstone Oncology Inc\u2019s upcoming earnings report date is Mar 07, 2024 which is in 15 days. How were Gritstone Oncology Inc\u2019s earnings last quarter? How were Gritstone Oncology Inc\u2019s earnings last quarter? Gritstone Oncology Inc released its earnings results on Nov 08, 2023. The company reported -$0.33 earnings per share for the quarter, beating the consensus estimate of -$0.34 by $0.01. ... According to Wall Street analysts Gritstone Oncology Inc\u2019s price is currently Undervalued. What happened to Gritstone Oncology Inc\u2019s price movement after its last earnings report? Gritstone Oncology Inc reported an EPS of -$0.33 in its last earnings report, beating expectations of -$0.34. Following the earnings report the stock price went down -7.692%. Following the earnings report the stock price went down -7.692%. Which hedge fund is a major shareholder of Gritstone Oncology Inc? Among the largest hedge funds holding Gritstone Oncology Inc\u2019s share is Versant Venture Management, LLC. It holds Gritstone Oncology Inc\u2019s shares valued at 7M. ... By 87.3K Shares Last Quarter.", + "page_result": "\n \nGritstone Oncology Inc (GRTS) Stock Price, Quote, News & Analysis - TipRanks.com\n\n\n\n\n\n\n \n \n \n\n \n \n \n \n \n \n \n
\"tipranks\"\"tipranks\"
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesDividend StocksChatGPT StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Stock ScreenerETF Screener
Popular
Compare StocksCompare ETFsTrending StocksTechnical Analysis ScreenerPenny Stock ScreenerDaily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Personal Finance CenterMortgagesLoansInvesting & RetirementSpending & Savings
Calculators
401k Retirement CalculatorMortgage Calculator
Popular
Compound Interest CalculatorDollar Cost Averaging
New
Student Loan CalculatorAuto Loan Calculator
Education
How To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksTipRanks CommunityContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
\"\"/\"\"/\"\"/\"\"/\"\"/\"\"/
TOOLS
My Portfolio
My Watchlist
Earnings Calendar
Stock Screener
Penny Stocks
Top Stocks
ETF Center
STOCKS
BABA
AAPL
SPY
AMZN
QQQ
TSLA
NVDA
ADVANCED RESEARCH
TipRanks Premium
Invest Like a Pro with Unique Data & Simplifed ToolsTry Now
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
Dividend Stocks
ChatGPT Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Research Tools
Stock Screener
ETF Screener
Popular
Compare Stocks
Compare ETFs
Trending Stocks
Technical Analysis Screener
Penny Stock Screener
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
TipRanks Community
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us
Gritstone Oncology Inc (GRTS)
NASDAQ:GRTS
GRTS
Gritstone Oncology
Stock Analysis
Analyst Forecasts
Technical Analysis
Options
Chart
Earnings
Dividends
Ownership
Financials
Stock Buybacks
News & Insights
Similar Stocks
RESEARCH TOOLS
Top Analyst Stocks
Top Smart Score Stocks
Stock Screener
reports

Gritstone Oncology (GRTS) Stock Price & Analysis

617 Followers

GRTS Stock Chart & Stats

Advanced Chart >
Day\u2019s Range$0 - $0
52-Week Range$1.14 - $3.33
Previous Close$2.07
Volume709.63K
Average Volume (3M)1.89M
Market Cap
$213.16M
Enterprise Value$209.66M
Total Cash (Recent Filing)$83.95M
Total Debt (Recent Filing)$95.30M
Price to Earnings (P/E)-1.6
Beta1.48
Next Earnings
Mar 07, 2024
EPS Estimate
-$0.34
Next Dividend Ex-DateN/A
Expense RatioN/A
Share Statistics
EPS (TTM)-1.30
Shares Outstanding95,342,055
10 Day Avg. Volume1,147,026
30 Day Avg. Volume1,891,388
Standard Deviation0.51
R-Squared0.00210
Alpha0.00452
Financial Highlights & Ratios
Price to Book (P/B)2.29
Price to Sales (P/S)8.60
Price to Cash Flow (P/CF)-1.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue20.51
Enterprise Value/Gross Profit10.51
Enterprise Value/Ebitda-1.54
Forecast
1Y Price Target
$10.75
Price Target Upside383.15% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4

Gritstone Oncology News

\"Gritstone
Press ReleasesGritstone bio to Participate in Upcoming Investor and Scientific Conferences
7d ago
GRTS
\"Gritstone
Company AnnouncementsGritstone Oncology Postpones Phase 2b COVID-19 Vaccine Trial
16d ago
8K
GRTS
\"Gritstone
The FlyGritstone announces update to comparative Phase 2b COVID-19 trial
16d ago
GRTS
\"Gritstone
The FlyGritstone announces update to comparative Phase 2b COVID-19 trial
16d ago
GRTS
\"Gritstone
Press ReleasesGritstone bio Announces Update to Comparative Phase 2b COVID-19 Clinical Trial
16d ago
GRTS
\"Gritstone
Press ReleasesGritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
20d ago
GRTS
\"5
Stock Analysis & Ideas5 Top Penny Stocks to Buy Now, According to Analysts \u2013 January 2024
1M ago
ASUR
EMKR
\"Gritstone
Press ReleasesGritstone bio to Participate in Upcoming Investor Conference
1M ago
GRTS
See More GRTS News >

Financials

Annual
Income Statement >

Options Prices

Detailed Option Prices >

Ownership Overview

24.34%9.48%29.48%36.70%
24.34% Insiders
9.48% Mutual Funds
29.48% Other Institutional Investors
36.70% Public Companies and
Individual Investors
Detailed Ownership Overview >

Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company\u2019s reliance on technology and ability to make innovative products
\"\"/
Detailed Risk Analysis >

Website Traffic

\"\"/Sorry, No Data Available
There is no website visitor data available for this stock.
---

GRTS FAQ

What was Gritstone Oncology Inc\u2019s price range in the past 12 months?
Gritstone Oncology Inc lowest stock price was $1.14 and its highest was $3.33 in the past 12 months.
    What is Gritstone Oncology Inc\u2019s market cap?
    Currently, no data Available
    When is Gritstone Oncology Inc\u2019s upcoming earnings report date?
    Gritstone Oncology Inc\u2019s upcoming earnings report date is Mar 07, 2024 which is in 8 days.
      How were Gritstone Oncology Inc\u2019s earnings last quarter?
      Gritstone Oncology Inc released its earnings results on Nov 08, 2023. The company reported -$0.33 earnings per share for the quarter, beating the consensus estimate of -$0.34 by $0.01.
        Is Gritstone Oncology Inc overvalued?
        According to Wall Street analysts Gritstone Oncology Inc\u2019s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Gritstone Oncology Inc pay dividends?
          Gritstone Oncology Inc does not currently pay dividends.
          What is Gritstone Oncology Inc\u2019s EPS estimate?
          Gritstone Oncology Inc\u2019s EPS estimate is -$0.34.
            How many shares outstanding does Gritstone Oncology Inc have?
            Gritstone Oncology Inc has 95,342,060 shares outstanding.
              What happened to Gritstone Oncology Inc\u2019s price movement after its last earnings report?
              Gritstone Oncology Inc reported an EPS of -$0.33 in its last earnings report, beating expectations of -$0.34. Following the earnings report the stock price went down -7.692%.
                Which hedge fund is a major shareholder of Gritstone Oncology Inc?
                Among the largest hedge funds holding Gritstone Oncology Inc\u2019s share is Versant Venture Management, LLC. It holds Gritstone Oncology Inc\u2019s shares valued at 7M.
                  ---

                  Gritstone Oncology Stock Smart Score

                  7
                  Neutral
                  1
                  2
                  3
                  4
                  5
                  6
                  7
                  8
                  9
                  10

                  Analyst Consensus

                  Strong Buy
                  Average Price Target:
                  $10.75 (383.15% Upside)

                  Blogger Sentiment

                  Bullish
                  GRTS Sentiment 100%
                  Sector Average 70%

                  Hedge Fund Trend

                  Decreased
                  By 87.3K Shares
                  Last Quarter.

                  Crowd Wisdom

                  Very Positive
                  Last 7 Days \u25b2 1.6%
                  Last 30 Days \u25b2 12.3%

                  News Sentiment

                  Neutral
                  Bullish news 50%
                  Bearish news 50%

                  Technicals

                  SMA
                  Positive
                  20 days / 200 days
                  Momentum
                  -17.85%
                  12-Months-Change

                  Fundamentals

                  Return on Equity
                  -131.82%
                  Trailing 12-Months
                  Asset Growth
                  -8.78%
                  Trailing 12-Months
                  Top Smart Score Stocks >

                  Company Description

                  Gritstone Oncology Inc

                  Gritstone Oncology, Inc. clinical-stage biotechnology company, which engages in developing the next generation of cancer immunotherapies to fight multiple cancer types. The company was founded in August 2015 by Andrew Allen, Timothy Chan, Mark Cobbold, Graham Lord, Naiyer Rizvi and Jean-Charles Soria and is headquartered in Emeryville, CA.
                  ---

                  GRTS Stock 12 Months Forecast

                  Average Price Target

                  $10.75
                  \u25b2(383.15% Upside)
                  \n {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"plus_tr_sans","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","21":"$21","5.25":"$5.25","10.5":"$10.5","15.75":"$15.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":20,"label":{"className":"overflowvisible_force","align":"right","x":60,"y":-17.5,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n  <span style=\"color:#199ca5\">$20.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10.75,"label":{"className":"overflowvisible_force","align":"right","x":60,"y":-7.5,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n  <span style=\"color:#828080\">$10.75</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6,"label":{"className":"overflowvisible_force","align":"right","x":60,"y":2.5,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n  <span style=\"color:#912767\">$6.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,5.25,10.5,15.75,21],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2023","6":"Aug<br/>2023","9":"Nov<br/>2023","12":"Feb<br/>2024","25":"Feb<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.3,3.6615384615384614,5.023076923076923,6.384615384615384,7.746153846153846,9.107692307692307,10.46923076923077,11.830769230769231,13.192307692307693,14.553846153846155,15.915384615384617,17.276923076923076,18.638461538461538,{"y":20,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.3,2.9499999999999997,3.5999999999999996,4.25,4.8999999999999995,5.549999999999999,6.199999999999999,6.849999999999999,7.499999999999999,8.149999999999999,8.799999999999999,9.45,10.099999999999998,{"y":10.75,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.3,2.5846153846153843,2.869230769230769,3.1538461538461537,3.4384615384615382,3.7230769230769227,4.007692307692308,4.292307692307692,4.576923076923077,4.861538461538461,5.146153846153846,5.430769230769231,5.715384615384615,{"y":6,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.71,"date":1676592000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.55,"date":1677801600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.77,"date":1680825600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.52,"date":1683244800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.06,"date":1685664000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.93,"date":1688688000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.79,"date":1691107200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.83,"date":1693526400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.85,"date":1696550400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.88,"date":1698969600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.53,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.96,"date":1704412800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.3,"date":1706832000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}\n
                  Detailed Analyst Forecast >

                  Technical Analysis

                  Overall Consensus
                  Sell
                  7Bullish
                  3Neutral
                  12Bearish
                  Bullish
                  Neutral
                  Bearish
                  Overall Consensus
                  7
                  3
                  12
                  Technical Analysis
                  5
                  3
                  2
                  Moving Averages
                  2
                  0
                  10
                  Technical Analysis >
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  MGNX
                  MacroGenics
                  \u2015
                  \u2015
                  ARVN
                  Arvinas Holding Company
                  \u2015
                  \u2015
                  NKTR
                  Nektar Therapeutics
                  \u2015
                  \u2015
                  Compare GRTS Stocks >

                  Best Analysts Covering GRTS

                  1 Year
                  \"\"/
                  Sean Lee CFAH.C. Wainwright
                  1 Year Success Rate
                  8/20 ratings generated profit
                  40%
                  1 Year Average Return
                  +1.14%
                  reiterated a buy rating 16 days ago
                  Copying Sean Lee CFA's trades and holding each position for 1 Year would result in 40.00% of your transactions generating a profit, with an average return of +1.14% per trade.
                  Best Analyst Covering >
                  Popular Stocks
                  ---

                  Get More with TipRanks Premium

                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis
                  Subscribe NowSee Plans & Pricing
                  \"ios\"/\"android\"/
                  \"tipranks\"/
                  TipRanks is a comprehensive research tool that helps investors make better, data-driven investment decisions.
                  Find Us on
                  \"twitter\"/\"stocktwits\"/\"facebook\"/\"linkedin\"/\"instagram\"/\"youtube\"/
                  Newsletter SubscriptionEnter your email to receive our newsletter
                  \"ios\"/\"android\"/
                  Terms of UsePrivacy PolicyFAQ
                  EducationHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
                  About usAbout TipRanksTipRanks CommunityContact UsCareersReviews
                  Working With TipRanksEnterprise SolutionsTop Online BrokersBecome an Affiliate
                  PlansPlans & PricingAPI for Institutions
                  Find Us on
                  \"twitter\"/\"stocktwits\"/\"facebook\"/\"linkedin\"/\"instagram\"/\"youtube\"/
                  \"ios\"/\"android\"/
                  Terms of UsePrivacy PolicyFAQ
                  Disclaimer: The TipRanks Smart Score performance is based on backtested results. Backtested performance is not an indicator of future actual results. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. Backtested results are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. General assumptions include: XYZ firm would have been able to purchase the securities recommended by the model and the markets were sufficiently liquid to permit all trading. Changes in these assumptions may have a material impact on the backtested returns presented. Certain assumptions have been made for modeling purposes and are unlikely to be realized. No representations and warranties are made as to the reasonableness of the assumptions. This information is provided for illustrative purposes only. Backtested performance is developed with the benefit of hindsight and has inherent limitations. Specifically, backtested results do not reflect actual trading or the effect of material economic and market factors on the decision-making process. Since trades have not actually been executed, results may have under- or over-compensated for the impact, if any, of certain market factors, such as lack of liquidity, and may not reflect the impact that certain economic or market factors may have had on the decision-making process. Further, backtesting allows the security selection methodology to be adjusted until past returns are maximized. Actual performance may differ significantly from backtested performance. Backtested results are adjusted to reflect the reinvestment of dividends and other income and, except where otherwise indicated, are presented gross-of fees and do not include the effect of backtested transaction costs, management fees, performance fees or expenses, if applicable. Please note all regulatory considerations regarding the presentation of fees must be taken into account. No cash balance or cash flow is included in the calculation.
                  \n \n \n \n \n
                  ", + "page_last_modified": " Wed, 28 Feb 2024 15:05:09 GMT" + } + ] +} \ No newline at end of file